اين يمكنك التبليغ عن الاحداث الجانية للأدوية واللقاحات
Where Can You Report your Adverse Drug Reactions or Adverse Events Following Immunization
This section provides a comprehensive overview of the procedures and tools available to Healthcare Professionals, Market Authorization Holders and the General Public to report adverse events associated with medicinal products and vaccines in Lebanon.
How to report
You can send the case reports using the following tools:
For Healthcare Professionals and the Public
The Lebanese National Pharmacovigilance Program has adapted two user-friendly tools: one for Adverse Drug Reactions (Vigimobile e-Reporting e-Form) and another for reporting Adverse Events Following Immunization (Vigimobile e-Form). Both tools may be accessed by healthcare professionals and the general public.
The VigiMobile e-Form and e-Reporting e-Form:
The VigiMobile e-Form and e-Reporting e-Form are the latest tools launched in January 2025 by the Lebanese National Pharmacovigilance Program. These digital platforms were introduced to enhance the reporting process, with the e-Reporting e-Form designed for Adverse Drug Reactions (ADRs) and the VigiMobile e-Form specifically for Adverse Events Following Immunization (AEFIs).
How to Download on Android Phones
Scan the QR Code by pressing the link
Click the three dots in the top-right corner
Choose Install app
VigiMobile e-Form/e-Reporting e-Form now appears as an app
How to Download on Apple IOS Phones
Scan the QR Code by pressing the link
Click on the share button
Add VigiMobile to the home screen
VigiMobile e-Form/e-Reporting e-Form now appears as an app
How to Download on Windows
Press on the link
Install from the Browser menu
VigiMobile e-Form/e-Reporting e-Form is now installed
Phone number of the Quality Assurance of Pharmaceutical Products Program: 01-830254
For Market Authorization Holders:
Based on the Ministerial Resolution MR #181 issued in 2021, MAHs should adhere to the internationally agreed ICH guidelines and standards and send the reports in XML format as specified in ICH E2B (R2 or R3) guidelines